
MYRIAD GENETICS INC
Nasdaq · In Vitro & In Vivo Diagnostic Substances
Company Overview
A concise company profile alongside the latest public filing activity.
Myriad Genetics develops and markets molecular diagnostic tests that assess genetic risk for diseases such as hereditary cancers, and offers testing related to prenatal screening, pharmacogenomics, and tumor profiling to guide treatment decisions.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Davis Mark StevenDirector | Sell | $34K | 6,100at $5.62 | Nov 18, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable MYGN activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.